Department of Digestive Surgery, Assistance Publique Hôpitaux de Marseille, Timone University Hospital, France.
Clinique de Chirurgie Digestive et Endocrinienne, Institut des Maladies de l'Appareil Digestif, University Hospital of Nantes, France.
Radiother Oncol. 2020 May;146:167-171. doi: 10.1016/j.radonc.2020.02.020. Epub 2020 Mar 12.
To assess the efficacy and safety of sacral nerve modulation (SNM) in patients with faecal incontinence (FI) after pelvic radiotherapy in comparison with results of SNM for FI related to other conditions.
Prospectively collected data from patients who underwent SNM therapy between January 2010 and December 2015 at 7 tertiary colorectal units were reviewed retrospectively. Patients with FI following pelvic radiotherapy were identified and matched (1:2) for age and sex with 38 patients implanted over the same period for FI without previous radiotherapy. The treatment was considered favourable if the patient reported any therapeutic benefit from SNM, had no further complaints or interventions and did not consider stopping the treatment. Long-term results, surgical revision and definitive explantation rates were compared.
Among 352 patients who received a permanent SNM implant, 19 (5.4%) had FI following pelvic radiotherapy. After a mean follow-up of 3.5 ± 1.9 years, the cumulative successful treatment rates were similar between the groups (p = 0.60). For patients with FI following pelvic radiotherapy, the cumulative success rates were 99.4% [85.4-99.8], 96.7% [78.1-99.6], 91.7% [70.4-98.1] and 74.6% [48.4-94.8] at 1, 2, 3 and 5 years respectively. The revision and definitive explantation rates for infection did not differ significantly.
The long-term success rate of SNM for FI after pelvic radiotherapy is similar to that of SNM for FI related to other more frequent conditions. Our study suggests that FI after pelvic radiotherapy could be improved with SNM without an increased risk of complication.
评估骶神经调节(SNM)治疗盆腔放疗后粪便失禁(FI)患者的疗效和安全性,并与其他病因 FI 患者的 SNM 治疗结果进行比较。
回顾性分析 2010 年 1 月至 2015 年 12 月在 7 家三级结直肠中心接受 SNM 治疗的患者的前瞻性收集数据。识别并匹配(1:2)在同一时期因 FI 接受 SNM 植入但无先前放疗的 38 例患者,年龄和性别相匹配。如果患者报告 SNM 治疗有任何疗效,没有进一步的抱怨或干预,并且不考虑停止治疗,则认为治疗是有利的。比较长期结果、手术修订和最终取出率。
在 352 例接受永久性 SNM 植入的患者中,有 19 例(5.4%)在盆腔放疗后出现 FI。平均随访 3.5±1.9 年后,两组的累积治疗成功率相似(p=0.60)。对于盆腔放疗后出现 FI 的患者,累积成功率分别为 99.4%[85.4-99.8]、96.7%[78.1-99.6]、91.7%[70.4-98.1]和 74.6%[48.4-94.8]在 1、2、3 和 5 年时。感染导致的修订和最终取出率无显著差异。
盆腔放疗后 FI 患者 SNM 的长期成功率与其他更常见病因 FI 患者的 SNM 治疗结果相似。我们的研究表明,SNM 可改善盆腔放疗后 FI,且并发症风险无增加。